CD274 and melanoma: Relative to baseline, T cells from patients with BRAFm melanoma (Cohort A), who initiated anti-PD-L1 therapy with atezolizumab in Cycle 2, had roughly stable cell surface PD-L1 concentrations after Cycle 1 of neoadjuvant therapy and decreased cell surface PD-L1 after Cycle 3 (completion of neoadjuvant therapy) and Cycle 4 (surgery) (Fig. 5C).